Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Supratik Bhattacharyya"'
Autor:
Vibhu R. Khare, Binayak Sinha, Nilanjan Sengupta, Sudip Chatterjee, Debasish Maji, Anirban Majumder, Prathama Guha, Sujata Datta, Dinesh K. Hawelia, Supratik Bhattacharyya, Soumyabrata R. Chaudhuri, Masood Batin
Publikováno v:
Indian Journal of Endocrinology and Metabolism, Vol 28, Iss 3, Pp 239-249 (2024)
Idiopathic hirsutism (IH) is a common clinical condition with multiple diagnostic and therapeutic uncertainties. There are no clear recommendations for the diagnosis and management of the condition. This practice update was developed to guide the pri
Externí odkaz:
https://doaj.org/article/8dad29226b9247f5931dd08d7c4ff93d
Autor:
Kartik Varadarajan, Amy R. Sharn, Ganesh Kadhe, Irfan Shaikh, Suela Sulo, Supratik Bhattacharyya
Publikováno v:
Clinical Nutrition Open Science, Vol 55, Iss , Pp 193-204 (2024)
Summary: Background and Aims: Low muscle strength is strongly tied to poor nutrition status, and nutritional interventions are likewise linked to maintenance and restoration of muscle strength and functional status. Nutrition plays a vital role in mu
Externí odkaz:
https://doaj.org/article/95d62ac0436b43ffb99000f98a7aaaca
Autor:
Kirti Samudra, Aravinda Jagadeesha, Sanjay Kalra, Deepak Khandelwal, Sharvil Gadve, Supratik Bhattacharyya
Publikováno v:
Clinical Diabetology. 10:337-341
Objective To evaluate efficacy of gliclazide extended release (XR) 60 mg + metformin XR 500 mg fixed-dose combination (FDC) with metformin as add-on (as needed) in real-world clinical practice. Methods This prospective observational study was perform
Publikováno v:
INDIAN JOURNAL OF APPLIED RESEARCH. :42-44
Many T2DM patients are reluctant to continue injectable insulin therapy affecting medication adherence. The objective was to investigate the clinical effectiveness with empagliozin/linagliptin (EMPA/LINA) combination in patients unwilling to conti
Autor:
RAKESH M. PARIKH, AMIT GUPTA, BANSHI D. SABOO, VASANTH K. CH, SANJAY AGARWAL, BRIJ M. MAKKAR, SUPRATIK BHATTACHARYYA, SACHIN CHITTAWAR, ARUN NANDITHA, RAJIV R. KOVIL, SR., PURVI M. CHAWLA
Publikováno v:
Diabetes. 71
Background: Several studies have suggested that prevalence of diabetes in India is increasing, a large number of people remain undiagnosed, and overall glycemic control is poor among patients with diabetes. Although there is paucity of data from larg
Autor:
BANSHI D. SABOO, RAKESH M. PARIKH, AMIT GUPTA, VASANTH K. CH, BRIJ M. MAKKAR, SANJAY AGARWAL, PURVI M. CHAWLA, RAJIV R. KOVIL, SUPRATIK BHATTACHARYYA, SACHIN CHITTAWAR, ARUN NANDITHA
Publikováno v:
Diabetes. 71
Background: Central obesity is a risk factor for cardiovascular and metabolic disorders including diabetes, hypertension and dyslipidemia. Index of central obesity (ICO) , defined as ratio of waist circumference and height, has been earlier proposed
Autor:
AMIT GUPTA, BANSHI D. SABOO, RAKESH M. PARIKH, VASANTH K. CH, SANJAY AGARWAL, BRIJ M. MAKKAR, RAJIV R. KOVIL, SR., PURVI M. CHAWLA, ARUN NANDITHA, SUPRATIK BHATTACHARYYA, SACHIN CHITTAWAR
Publikováno v:
Diabetes. 71
Background: The ADA 2022 standard of care recommends routine screening for T2DM beginning from the age of 35 years, while Indian Council of Medical Research recommends to begin screening above the age of 30 years. Current study was aimed at assessing
Autor:
Supratik Bhattacharyya
Publikováno v:
Clinical Diabetology. 11:298-299
Autor:
Supratik Bhattacharyya
Publikováno v:
Clinical Diabetology. 9:233-238
Background. Antidiabetic agents such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose cotransporter-2 inhibitors (SGLT2i) are known to improve glycaemic control with favourable impact on cardiovascular (CV) risk factors. Giv